<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804100</url>
  </required_header>
  <id_info>
    <org_study_id>4241616009G</org_study_id>
    <nct_id>NCT02804100</nct_id>
  </id_info>
  <brief_title>Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients</brief_title>
  <official_title>A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre observational, non-interventional study is to dynamically monitor the changes
      of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dynamic changes of circulating tumor DNA in late stage NSCLC patients under Gefitinib treatment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Bronchial Neoplasms</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Lung Diseases</condition>
  <condition>Lung Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC patients with activating EGFR mutations
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Histologically confirmed stage IIIB/IV NSCLC.

          -  Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)

          -  Able to comply with the required protocol and followed-up procedures, and able to
             receive oral medications

        Exclusion Criteria:

          -  Histologically confirmed small cell lung cancer or other metastatic tumors

          -  Patient had received prior chemotherapy or EGFR-TKIs treatment

          -  Patients who harbor Exon20 T790M mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenfeng Li, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Wenzhou Medical Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunming Ding, Ph.D</last_name>
    <phone>86-755-86690871</phone>
    <email>cmdingchina@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ju Luan, Ph.D</last_name>
    <phone>86-755-86690871</phone>
    <email>luanluanjuju@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju Luan, PhD</last_name>
      <email>luanluanjuju@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenfeng Li, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Chunming Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Plasma DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

